All In Biotech

Investigational drug · Phase 2

RBP-01

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Uveal Melanoma.

Phase 2

Last checked: Nov 19, 2026Latest source record: Aug 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

1

Any phase or sponsor naming "RBP-01"

First trial start

2026

Oct 1, 2026

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "RBP-01", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Uveal Melanoma

Approved drugs for the same conditions: Melanoma · Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "RBP-01" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Uveal Melanoma

  • DarovasertibIDE 196, LXS196Phase 35 trials

    IDEAYA Biosciences · Uveal Melanoma, Metastatic Uveal Melanoma, Cutaneous Melanoma

  • AU-011Bel-sarPhase 32 trials

    Aura Biosciences · Choroidal Melanoma, Indeterminate Lesions, Uveal Melanoma

  • APG-115Phase 24 trials

    Ascentage Pharma Group Inc. · T-Prolymphocytic Leukemia, Non-Hodgkins Lymphoma, Liposarcoma

  • roginolisibIOA-244Phase 23 trials

    iOnctura · Myelofibrosis (MF), Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Advanced Non Squamous NSCLC

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.